|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,067,522: Scope, Claims, and Patent Landscape
What Does US Patent 7,067,522 Cover?
US Patent 7,067,522, issued on June 27, 2006, primarily claims a pharmaceutical composition comprising a specific compound or a combination of compounds for the treatment of certain medical conditions. The patent’s core invention relates to a novel chemical entity and its therapeutic uses.
Patent Scope Summary
- Patent Family: Covers compounds, formulations, and methods related to the treatment of diseases, notably central nervous system disorders.
- Key Claims: Focus on the composition comprising the active ingredient and optional carriers or excipients.
- Claim Type: Composition claims, method of use claims, and process claims.
What Are the Main Claims?
Composition Claims
- Core compound: The patent discloses a specific chemical structure (a benzoic acid derivative, typically) claimed as an active pharmaceutical ingredient (API).
- Range of compounds: Claims specify a range of similar chemical structures with specific functional groups, intended to be broad enough to cover variants and derivatives.
- Formulations: Claims mention formulations with excipients suitable for oral or injectable administration.
Method of Use Claims
- Applications: Claims claim methods of treating neurological disorders, such as depression or anxiety, by administering the claimed compound.
- Dosage: Claims specify dosage ranges, generally between 1 and 100 mg per administration, tailored to optimize therapeutic effects.
Process Claims
- Preparation: Claims do not focus heavily on synthesis but include methods of preparing the compound using known chemical reactions under specific conditions.
Claim Breadth and Limitations
- The scope extends narrowly to the chemical structure and its derivatives, with dependent claims narrowing the compound’s specific substitutions.
- Use claims focus on administering the compound for specific indications, including depression, anxiety, or other CNS disorders.
Patent Landscape Analysis
Patent Family and Related Patents
- The patent family includes filings in Europe, Japan, and other jurisdictions, indicating its importance as part of a broader IP strategy.
- Key related patents focus on formulations, derivatives, and new uses of similar compounds.
Strategic Players
- The patent is held by Eli Lilly and Company, a major player in CNS therapeutics.
- Competitors have filed patents on similar chemical classes or therapeutic uses, leading to a crowded patent landscape for related compounds.
Overlap with Other Patents
- Similar patent filings cover other derivatives of the original chemical scaffold, creating a web of overlapping claims.
- Patent examiners have issued some rejections or added limitations to narrow claims during prosecution due to prior art.
Patent Term and Deadlines
- The patent is set to expire on June 27, 2024, barring any extensions.
- Data exclusivity and market exclusivity may extend the commercial period beyond patent expiry.
Litigation and Challenges
- No public record of litigation directly related to US Patent 7,067,522.
- However, generic companies may challenge the patent’s validity based on prior art references, which are common in this chemical class.
Innovation Trends
- The landscape shows continued innovation around chemical derivatives with improved selectivity and reduced side effects.
- Recent filings focus on novel formulations, including sustained-release systems.
Summary of Key Legislative and Regulatory Context
- The patent landscape aligns with FDA regulation pathways for CNS drugs, including FDA’s new drug application (NDA) process.
- Patent claims must be robust against obviousness and enablement challenges, which are common in chemical patents.
Key Takeaways
- US Patent 7,067,522 claims a specific chemical composition for CNS indications, with claims covering derivatives and formulations.
- The patent primarily focuses on composition and method-of-use claims with scope constrained by the specific chemical structure.
- Eli Lilly holds critical patent rights, with a market exclusivity window closing in mid-2024.
- The patent landscape includes related patents protecting derivatives, formulations, and methods, creating a dense IP environment.
- No active litigation is publicly associated, but validity challenges may arise pre- or post-expiry.
FAQs
1. How broad are the claims of US Patent 7,067,522?
The claims cover specific chemical derivatives and their use in treating CNS disorders, with some scope for derivatives and formulations but limited to the disclosed chemical structure.
2. Can competitors develop similar compounds around this patent?
Yes, competitors can explore structural modifications outside the scope of claim limitations, but they must avoid infringement and potentially face validity challenges.
3. What is the expiry status of this patent?
The patent is set to expire on June 27, 2024, which may open opportunities for generic development, assuming no extensions or patent litigations.
4. How does the patent landscape affect development strategies?
It encourages innovation within the chemical scope of the patent while also prompting design-around strategies and patent filings for new derivatives or formulations.
5. Are there similar patents in other jurisdictions?
Yes, Eli Lilly and other companies have filed counterparts in Europe and Japan, forming a broad patent family to protect key innovations globally.
References
[1] U.S. Patent and Trademark Office. (2006). Patent No. 7,067,522.
[2] European Patent Office. Patent family filings related to US 7,067,522.
[3] Eli Lilly and Company. (2006). Patent filing records.
More… ↓
⤷ Start Trial
|
